Get the Stockscreener App
53.86
1.39%
-0.76
After Hours:
53.86
Protagonist Therapeutics Inc stock is traded at $53.86, with a volume of 561.12K.
It is down -1.39% in the last 24 hours and down -2.55% over the past month.
Protagonist Therapeutics Inc is a clinical-stage biopharmaceutical company having a proprietary technology platform that enables the discovery and development of novel constrained peptide-based drug candidates to address medical needs. Its pipeline products include Rusfertide (PTG-300) and JNJ-2113.
See More
Previous Close:
$54.62
Open:
$54.14
24h Volume:
561.12K
Relative Volume:
0.67
Market Cap:
$3.34B
Revenue:
$45.48M
Net Income/Loss:
$169.95M
P/E Ratio:
20.56
EPS:
2.62
Net Cash Flow:
$230.85M
1W Performance:
+0.22%
1M Performance:
-2.55%
6M Performance:
+42.49%
1Y Performance:
+43.86%
1-Day Range:
$53.69
$55.29
1-Week Range:
$53.06
$57.15
52-Week Range:
$32.50
$60.60
Protagonist Therapeutics Inc Stock (PTGX) Company Profile
Name
Protagonist Therapeutics Inc
Sector
Industry
Phone
(510) 474-0170
Address
7707 GATEWAY BLVD., SUITE 140, NEWARK, CA
Compare PTGX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PTGX
Protagonist Therapeutics Inc
|
53.86 | 3.39B | 45.48M | 169.95M | 230.85M | 2.62 |
|
VRTX
Vertex Pharmaceuticals Inc
|
456.87 | 120.48B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
545.46 | 59.88B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
392.24 | 44.31B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
670.33 | 36.65B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
301.13 | 32.46B | 3.81B | -644.79M | -669.77M | -6.24 |
Protagonist Therapeutics Inc Stock (PTGX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-17-25 | Initiated | Citigroup | Buy |
| Dec-06-24 | Initiated | BMO Capital Markets | Outperform |
| Dec-06-24 | Initiated | Goldman | Neutral |
| Nov-05-24 | Initiated | Wedbush | Outperform |
| Sep-24-24 | Initiated | TD Cowen | Buy |
| Sep-09-24 | Initiated | Truist | Buy |
| Oct-30-23 | Initiated | CapitalOne | Overweight |
| May-25-23 | Resumed | Jefferies | Buy |
| Aug-25-22 | Initiated | JMP Securities | Mkt Outperform |
| Feb-11-22 | Initiated | BTIG Research | Buy |
| Oct-12-21 | Upgrade | JP Morgan | Neutral → Overweight |
| Oct-11-21 | Upgrade | Northland Capital | Market Perform → Outperform |
| Sep-20-21 | Downgrade | JP Morgan | Overweight → Neutral |
| May-24-21 | Initiated | JMP Securities | Mkt Outperform |
| May-24-21 | Initiated | Northland Capital | Outperform |
| Jan-06-21 | Initiated | JP Morgan | Overweight |
| Dec-16-20 | Initiated | Piper Sandler | Overweight |
| Sep-18-20 | Reiterated | H.C. Wainwright | Buy |
| Jul-15-20 | Initiated | Jefferies | Buy |
| May-18-20 | Reiterated | H.C. Wainwright | Buy |
| Jul-08-19 | Initiated | H.C. Wainwright | Buy |
| May-09-19 | Upgrade | Stifel | Hold → Buy |
| Dec-06-18 | Initiated | Nomura | Buy |
| Jan-29-18 | Initiated | Stifel | Buy |
| Jul-21-17 | Initiated | BTIG Research | Buy |
View All
Protagonist Therapeutics Inc Stock (PTGX) Latest News
What is Protagonist Therapeutics Inc. company’s growth strategyPost Market Guidance For Smart Trading - jammulinksnews.com
What are the latest earnings results for Protagonist Therapeutics Inc.Free Stock Watchlist For Fast Growth - jammulinksnews.com
Does Protagonist Therapeutics Inc. stock perform well during market downturnsValue Investing Tips For Fast Growth - jammulinksnews.com
Protagonist Therapeutics Inc. Company’s Quarterly Earnings Growth: What the Numbers SayConservative Long Term Growth Plans Under Review - metal.it
Protagonist Therapeutics Inc. Crosses 200 Day MA — Signal or NoiseHigh Return Stock Focus With Safety Emphasized - metal.it
Protagonist Therapeutics' CEO Insider Sale: Signal or Noise Amid Strong Analyst Optimism? - AInvest
Protagonist Therapeutics Inc. Hits Oversold Level on RSI IndicatorCapital Efficiency Optimized Stock Alerts Reviewed - metal.it
Screener Results Flag Protagonist Therapeutics Inc. as OversoldTarget Return Focused Trade Insights Shared - beatles.ru
Protagonist therapeutics CEO Patel sells $570k in stock By Investing.com - Investing.com Canada
Published on: 2025-07-28 20:33:17 - metal.it
Published on: 2025-07-28 15:35:31 - metal.it
How does Protagonist Therapeutics Inc. generate profit in a changing economyDiscover top stock picks for aggressive growth - jammulinksnews.com
What is the dividend policy of Protagonist Therapeutics Inc. stockFree Stock Market Return Analysis - jammulinksnews.com
What are Protagonist Therapeutics Inc. company’s key revenue driversDaily Trading Picks Backed By Experts - jammulinksnews.com
What institutional investors are buying Protagonist Therapeutics Inc. stockCapitalize on market shifts before others do - jammulinksnews.com
What catalysts could drive Protagonist Therapeutics Inc. stock higher in 2025Capitalize on trading strategies that deliver - jammulinksnews.com
Is Protagonist Therapeutics Inc. a growth stock or a value stockGame-changing returns - jammulinksnews.com
Does Protagonist Therapeutics Inc. stock pay reliable dividendsFree Consultation - metal.it
Johnson & Johnson Submits NDA for Protagonist-Partnered Icotrokinra to FDA for Plaque Psoriasis - MSN
Protagonist Therapeutics Inc. Stock Analysis and ForecastExponentially increasing returns - PrintWeekIndia
What analysts say about Protagonist Therapeutics Inc. stockHigh-performance investment picks - PrintWeekIndia
Protagonist Therapeutics to Host Conference Call to Announce an Oral Obesity Development Candidate - Newport Daily News
CEO’s Major Stock Sale Shakes Up Protagonist Therapeutics! - TipRanks
Protagonist Therapeutics CEO Patel sells $2.88 million in shares By Investing.com - Investing.com India
Protagonist Therapeutics CEO Patel sells $2.88 million in shares - Investing.com
What drives Protagonist Therapeutics Inc. stock priceDynamic capital growth - Autocar Professional
Is Protagonist Therapeutics Inc. a good long term investmentBreakout stock performance - jammulinksnews.com
Protagonist Announces Submission of NDA for First Icotrokinra U.S. FDA Approval Aiming to Revolutionize Treatment Paradigm for Adults and Adolescents with Plaque Psoriasis - Lubbock Avalanche-Journal
Protagonist Therapeutics Inc Stock (PTGX) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.43%
2.00%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):